Patents by Inventor Laura A. Vitale

Laura A. Vitale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250115663
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: June 21, 2024
    Publication date: April 10, 2025
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
  • Publication number: 20250059291
    Abstract: The invention provides CD27 agonists comprising a first component that is an anti-CD27 antibody, or antigen-binding fragment thereof, linked to a second component comprising one or more cross-linking moieties. At least one of the cross-linking moieties does not bind to an Fc receptor and the CD27 agonist stimulates T cell activity without the need for Fc receptor interaction. The cross-linking molecule(s) can be, for example, an anti-CD27, antibody, or antigen-binding fragment thereof, that can be the same or different than the first component. Alternatively, the cross-linking molecule(s) can be a CD27 ligand or a molecule (e.g., antibody) that binds a molecule on a cell such as a T cell, a tumor cell or a stromal cell. Pharmaceutical compositions comprising the CD27 agonists, and methods of using the CD27 agonists, are also provided.
    Type: Application
    Filed: May 17, 2024
    Publication date: February 20, 2025
    Inventors: Tibor KELER, Joel GOLDSTEIN, Lizhen HE, Henry C. MARSH, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Laura A. VITALE, Jenifer WIDGER
  • Publication number: 20240417459
    Abstract: Provided herein are novel ILT4 antibodies, and antigen binding fragments thereof, as well as bispecific and multispecific constructs binding to ILT4 and PD-L1, comprising such antibodies linked to at least one additional binding agent. Methods of inducing or enhancing an immune response, and methods of treating cancer, by administering the antibodies (or fragments), bispecific constructs, or compositions also are described.
    Type: Application
    Filed: April 8, 2022
    Publication date: December 19, 2024
    Inventors: Tibor KELER, Joel GOLDSTEIN, Michael B. MURPHY, Thomas O'NEILL, Laura A. VITALE
  • Publication number: 20240409639
    Abstract: Provided herein are novel anti-ILT4 and anti-PD-1 bispecific constructs, as well as corresponding compositions. Meth-ods of inducing or enhancing an immune response, and methods of treating cancer, by administering the constructs or compositions also are described.
    Type: Application
    Filed: November 8, 2022
    Publication date: December 12, 2024
    Inventors: Tibor KELER, Joel GOLDSTEIN, Michael MURPHY, Thomas O'NEILL, Laura A. VITALE, Mingjiu CHEN
  • Publication number: 20220324990
    Abstract: Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.
    Type: Application
    Filed: April 14, 2022
    Publication date: October 13, 2022
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE
  • Patent number: 11459393
    Abstract: Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: October 4, 2022
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He
  • Publication number: 20220227877
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: October 22, 2021
    Publication date: July 21, 2022
    Inventors: Tibor KELER, Henry C. MARSH, Lizhen HE, Laura A. VITALE, Lawrence J. THOMAS
  • Publication number: 20220177593
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to Axl, a receptor tyrosine kinase. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer using the anti-Axl antibodies.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 9, 2022
    Applicant: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Diego Alvarado, Richard W. Gedrich, Joel Goldstein, Laura Vitale, Thomas O'Neill, Andrea Crocker, Jenifer Widger, Michael B. Murphy, Shannon Pankratz
  • Patent number: 11332537
    Abstract: Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: May 17, 2022
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He
  • Publication number: 20220025063
    Abstract: Provided herein are novel anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition (e.g., cancer) by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.
    Type: Application
    Filed: August 18, 2021
    Publication date: January 27, 2022
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE
  • Patent number: 11180566
    Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: November 23, 2021
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Henry C. Marsh, Lizhen He, Laura A. Vitale, Lawrence J. Thomas
  • Publication number: 20210198374
    Abstract: Provided herein are novel anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition (e.g., cancer) by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.
    Type: Application
    Filed: April 17, 2019
    Publication date: July 1, 2021
    Applicant: Celldex Therapeutics, Inc.
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE
  • Publication number: 20210147538
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 20, 2021
    Applicants: Celldex Therapeutics, Inc., Celldex Therapeutics, Inc.
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
  • Patent number: 10941201
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: August 6, 2020
    Date of Patent: March 9, 2021
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
  • Patent number: 10865244
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: December 15, 2020
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
  • Publication number: 20200377606
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: April 18, 2017
    Publication date: December 3, 2020
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
  • Publication number: 20200369768
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: August 6, 2020
    Publication date: November 26, 2020
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER
  • Patent number: 10633444
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: April 28, 2020
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
  • Publication number: 20200109207
    Abstract: Provided herein are novel anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition (e.g., cancer) by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.
    Type: Application
    Filed: April 17, 2019
    Publication date: April 9, 2020
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE
  • Publication number: 20190322743
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: April 5, 2019
    Publication date: October 24, 2019
    Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER